{"id":"https://openalex.org/W7150783756","doi":"https://doi.org/10.6084/m9.figshare.31942639","title":"Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study","display_name":"Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study","publication_year":2026,"publication_date":"2026-04-06","ids":{"openalex":"https://openalex.org/W7150783756","doi":"https://doi.org/10.6084/m9.figshare.31942639"},"language":"en","primary_location":{"id":"doi:10.6084/m9.figshare.31942639","doi":"https://doi.org/10.6084/m9.figshare.31942639","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.31942639","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"JournalArticle"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["datacite"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://doi.org/10.6084/m9.figshare.31942639","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5035466597","display_name":"Eziafa Oduah","orcid":"https://orcid.org/0000-0001-8517-6360","observed_orcids":["https://orcid.org/0000-0001-8517-6360"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Eziafa I. Oduah","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5133016548","display_name":"Tian Zhang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tian Zhang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023554560","display_name":"Sin\u2010Ho Jung","orcid":"https://orcid.org/0000-0002-1473-7236","observed_orcids":["https://orcid.org/0000-0002-1473-7236"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sin-Ho Jung","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014554706","display_name":"Thomas E. Stinchcombe","orcid":"https://orcid.org/0000-0002-3595-8011","observed_orcids":["https://orcid.org/0000-0002-3595-8011"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Thomas E. Stinchcombe","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079438136","display_name":"Neal Ready","orcid":"https://orcid.org/0000-0003-4414-9432","observed_orcids":["https://orcid.org/0000-0003-4414-9432"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Neal Ready","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006930823","display_name":"Jeffrey Crawford","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jeffrey Crawford","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5128302404","display_name":"Jeffrey M. Clarke","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jeffrey M. Clarke","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007121755","display_name":"Jhanelle E. Gray","orcid":"https://orcid.org/0000-0003-1304-7062","observed_orcids":["https://orcid.org/0000-0003-1304-7062"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jhanelle E. Gray","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5063392015","display_name":"Scott J. Antonia","orcid":"https://orcid.org/0000-0002-0029-9685","observed_orcids":["https://orcid.org/0000-0002-0029-9685"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Scott J. Antonia","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0031999999191612005,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alirocumab","display_name":"alirocumab","score":0.996999979019165},{"id":"https://openalex.org/keywords/cemiplimab","display_name":"cemiplimab","score":1.0},{"id":"https://openalex.org/keywords/metastatic-nsclc","display_name":"metastatic non-small cell lung cancer","score":0.9309999942779541},{"id":"https://openalex.org/keywords/pcsk9-inhibition","display_name":"PCSK9 inhibition","score":0.8320000171661377},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitor-resistance","display_name":"immune checkpoint inhibitor resistance","score":0.7120000123977661},{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.8899999856948853},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.8550000190734863},{"id":"https://openalex.org/keywords/antigen-presentation","display_name":"antigen presentation","score":0.7720000147819519},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.6629999876022339}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.770799994468689},{"id":"https://openalex.org/C2780902209","wikidata":"https://www.wikidata.org/wiki/Q4726914","display_name":"Alirocumab","level":5,"score":0.7177000045776367},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.5788000226020813},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.5504000186920166},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5252000093460083},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5178999900817871},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.4909999966621399},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.435699999332428},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.4334000051021576},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.4235999882221222},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.39089998602867126},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3853999972343445},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.37130001187324524},{"id":"https://openalex.org/C2780674031","wikidata":"https://www.wikidata.org/wiki/Q2012719","display_name":"Cancer immunotherapy","level":4,"score":0.36820000410079956},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.35989999771118164},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.34040001034736633},{"id":"https://openalex.org/C61238886","wikidata":"https://www.wikidata.org/wiki/Q5121689","display_name":"Circulating tumor cell","level":4,"score":0.3237999975681305},{"id":"https://openalex.org/C21705690","wikidata":"https://www.wikidata.org/wiki/Q2907609","display_name":"CTLA-4","level":4,"score":0.30480000376701355},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.2680000066757202},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.26579999923706055},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.26350000500679016},{"id":"https://openalex.org/C2776904630","wikidata":"https://www.wikidata.org/wiki/Q356336","display_name":"Adept","level":3,"score":0.2615000009536743}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.6084/m9.figshare.31942639","doi":"https://doi.org/10.6084/m9.figshare.31942639","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.31942639","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"JournalArticle"},{"id":"doi:10.6084/m9.figshare.31942639.v1","doi":"https://doi.org/10.6084/m9.figshare.31942639.v1","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.31942639.v1","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"JournalArticle"}],"best_oa_location":{"id":"doi:10.6084/m9.figshare.31942639","doi":"https://doi.org/10.6084/m9.figshare.31942639","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.31942639","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"JournalArticle"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/study-protocol","display_name":"Study Protocol"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4408981185","https://openalex.org/W7162535192","https://openalex.org/W7165798947","https://openalex.org/W4415519335","https://openalex.org/W4410818009","https://openalex.org/W4328115916","https://openalex.org/W7223042539","https://openalex.org/W2898120514","https://openalex.org/W4408050515","https://openalex.org/W2898251043"],"abstract_inverted_index":{"Immunotherapy":[0],"resistance":[1,42],"represents":[2],"a":[3,30,38,145,223,240,288],"major":[4],"unmet":[5],"clinical":[6,118],"need":[7],"for":[8,33,271],"patients":[9,79],"with":[10,80,101,250,255,273],"metastatic":[11,81],"non\u2013small":[12],"cell":[13],"lung":[14,257,297],"cancer":[15,159,174,191,232,258,262,298],"(NSCLC).":[16],"Preclinical":[17],"studies":[18],"have":[19,84,303],"identified":[20],"PCSK9":[21,35,72,148,171,224,289],"as":[22,37],"an":[23,61],"immunosuppressive":[24],"regulator":[25],"of":[26,59,70],"antigen":[27],"presentation,":[28],"providing":[29],"compelling":[31],"rationale":[32,55],"therapeutic":[34],"inhibition":[36],"strategy":[39,125],"to":[40,43,75,115,206,219,226,236],"overcome":[41],"immune":[44,90,165,187,294],"checkpoint":[45,91],"blockade.":[46],"Building":[47],"on":[48,88,122,180,265],"this":[49,123,139,280],"evidence,":[50],"we":[51],"present":[52],"the":[53,68,71,127,163,186,190,293],"scientific":[54],"and":[56,108,119,192,204,214],"study":[57,140,269],"design":[58],"TOP2201,":[60],"ongoing":[62],"single-arm":[63],"phase":[64,241],"II":[65,242],"trial":[66],"evaluating":[67],"addition":[69],"inhibitor":[73],"alirocumab":[74,249],"anti\u2013PD-1":[76],"therapy":[77],"in":[78,126,300],"NSCLC":[82,129],"who":[83,302],"experienced":[85],"disease":[86],"progression":[87],"prior":[89],"inhibitor\u2013based":[92],"regimens.":[93],"The":[94,268],"primary":[95],"endpoint":[96],"is":[97,135,138,172,239,245,270],"objective":[98],"response":[99],"rate,":[100],"secondary":[102],"endpoints":[103],"assessing":[104],"additional":[105],"efficacy":[106],"outcomes":[107],"safety.":[109],"Findings":[110],"from":[111,162],"TOP2201":[112,238,283],"are":[113,201,212],"expected":[114],"generate":[116],"preliminary":[117],"safety":[120],"data":[121],"combination":[124],"immunorefractory":[128],"setting.Clinical":[130],"Trial":[131],"Registration:":[132],"www.clinicaltrials.gov":[133],"identifier":[134],"NCT05553834.":[136],"Why":[137],"needed?":[141],"Scientists":[142],"found":[143],"that":[144,196,286],"protein":[146],"called":[147],"does":[149],"more":[150,177],"than":[151],"help":[152,158,185,229,253,292],"control":[153],"cholesterol.":[154,208],"It":[155,244],"may":[156,284],"also":[157],"cells":[160,175],"hide":[161],"body\u2019s":[164],"system.":[166],"In":[167],"lab":[168],"tests,":[169],"when":[170],"blocked,":[173],"keep":[176],"\u201cID":[178],"tags\u201d":[179],"their":[181,261],"surface.":[182],"These":[183],"tags":[184],"system":[188,295],"see":[189,220],"attack":[193],"it.":[194],"Medicines":[195],"block":[197],"PCSK9,":[198],"like":[199],"alirocumab,":[200],"already":[202],"approved":[203],"used":[205],"lower":[207],"Because":[209],"these":[210],"medicines":[211],"safe":[213],"well":[215],"known,":[216],"doctors":[217],"want":[218],"if":[221],"adding":[222,287],"blocker":[225,290],"immunotherapy":[227],"can":[228,252,291],"people":[230,254,301],"whose":[231],"no":[233],"longer":[234],"responds":[235],"treatment.":[237],"study.":[243],"testing":[246],"whether":[247],"using":[248],"cemiplimab":[251],"advanced":[256],"(NSCLC)":[259],"after":[260],"has":[263],"grown":[264],"earlier":[266],"immunotherapy.":[267],"adults":[272],"stage":[274],"IV":[275],"NSCLC.":[276],"Potential":[277],"impact:":[278],"If":[279],"treatment":[281],"works,":[282],"show":[285],"fight":[296],"again":[299],"very":[304],"few":[305],"options":[306],"left.":[307]},"counts_by_year":[],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2026-04-07T00:00:00"}